HUNT VALLEY, Md.--(BUSINESS WIRE)--Feb. 7, 2006--CepTor Corporation (OTC BB:CEPO), a development-staged biopharmaceutical company focusing on cell-targeted therapeutic products for neuromuscular and neurodegenerative diseases, announced that Banyan Biomarkers, Inc. has been retained to identify a biomarker assay that evaluates the usefulness of Myodur for treating Duchenne Muscular Dystrophy (DMD) in children. Biomarkers, proteins found in body fluids, are crucial in determining a drug’s efficacy and toxicity and have the potential to significantly reduce a company’s clinical trial costs and duration. Used early in the development process, biomarkers are also key in improving patient selection in clinical trials and rapidly determining potentially therapeutic doses.
